Evidence map›Paper›PMID 41290674›Full record

ArticleNature communications2025

Remission spectroscopy resolves the mechanism of action of bedaquiline within living mycobacteria.

Suzanna H Harrison, Rowan C Walters, Chen-Yi Cheung, Roger J Springett, Gregory M Cook, Morwan M Osman, James N Blaza

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Suzanna H Harrison *York Structural Biology Laboratory, Department of Chemistry, University of York, York, UK.
Rowan C Walters *York Structural Biology Laboratory, Department of Chemistry, University of York, York, UK.ORCID http://orcid.org/0000-0002-1067-8494
Chen-Yi CheungDepartment of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
Roger J SpringettYork Structural Biology Laboratory, Department of Chemistry, University of York, York, UK.
Gregory M CookDepartment of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
Morwan M Osman *York Structural Biology Laboratory, Department of Chemistry, University of York, York, UK. morwan.osman@york.ac.uk.ORCID http://orcid.org/0000-0002-5361-743X
James N BlazaYork Structural Biology Laboratory, Department of Chemistry, University of York, York, UK. jamie.blaza@york.ac.uk.ORCID http://orcid.org/0000-0001-5420-2116

Funding

RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/X003035/1
6 · The paper itself

Abstract

Bedaquiline, an ATP synthase inhibitor, is the spearhead of transformative therapies against drug-resistant Mycobacterium tuberculosis. Here, we use remission spectroscopy to measure the energy-transducing cytochromes within unperturbed, respiring suspensions of mycobacterial and human cells, allowing spectroscopic measurements of electron transport chains as they power living cells and respond to bedaquiline. No evidence is found for protonophoric or ionophoric uncoupling. Rather, by directly inhibiting ATP synthase, bedaquiline slows the respiratory supercomplex (Qcr:Cta; bcc:aa

Indexed as

Antitubercular AgentsDiarylquinolinesMycobacterium tuberculosisSpectrum AnalysisElectron TransportHumansOxygen ConsumptionProton-Motive ForceAntitubercular AgentsbedaquilineDiarylquinolines

Identifiers

PMID41290674
PMCPMC12695928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.